1 asset in B-Cell Childhood Acute Lymphoblastic Leukemia

Therapeutic assets addressing B-Cell Childhood Acute Lymphoblastic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Blinatumomab B-Cell Childhood Acute Lymphoblastic Leukemia	Seoul National University Hospital	P2	B (60)